Conflict of interest: E.T.K. reports receiving lecture fees from Astellas, Abbott, Amgen, AstraZeneca, Boehringer
Ingelheim, Bristol-Myers Squibb, Eli-Lilly Japan KK, Daiichi-Sankyo, Menarini, Ono
Pharmaceutical, Ootsuka Pharmaceutical, MSD KK, Takeda Pharmaceutical, Tanabe-Mitsubishi,
Bayer, Pfizer; consultant fee from Boehringer Ingelheim and Daiichi-Sankyo; research
fund from Abbott, Ono Pharmaceutical, and Tanabe-Mitsubishi;
D.M. reports grants to the Brigham and Women’s Hospital from Abbott Laboratories, Amgen,
Anthos Therapeutics, AstraZeneca, Eisai, Medicines Co., Merck, Novartis, Pfizer, Roche
Diagnostics, and Siemens; and consultant fees from InCardia, Inflammatix, Merck &
Co, Novartis, and Roche Diagnostics. D.M. is a member of the TIMI Study Group, which
has received institutional research grant support through Brigham and Women’s Hospital
from Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Bayer, Daiichi-Sankyo,
Eisai, Intarcia, Ionis Pharmaceuticals, MedImmune, Merck, Novartis, Pfizer, Quark
Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics,
The Medicines Company, and Zora Biosciences; J.G. is a member of the TIMI Study Group
which has received institutional research grant support through Brigham and Women’s
from Abbott Laboratories, Amgen; AstraZeneca; Critical Diagnostics, Daiichi-Sankyo;
Eisai; Genzyme; Gilead; GlaxoSmithKline; Intarcia; Janssen Research and Development;
Medicines Company; MedImmune; Merck; Novartis; Pfizer; Poxel; Roche Diagnostics; and
Takeda; D.D.B. is supported by Harvard Catalyst KL2/CMeRIT (NIH/NCATS grant UL 1TR002541).
He has received research grant support to his institution from AstraZeneca and Pfizer;
consulting fees from AstraZeneca; and participates on a clinical endpoint committee
for a study sponsored by Kowa Pharmaceuticals. M.B. has no conflict of interest; E.A.B.
is a member of the TIMI Study Group which has received institutional research grant
support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics,
AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia,
MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals,
Inc., Roche, Siemens Healthcare Diagnostics, Inc., The Medicines Company, Zora Biosciences.
E.A.B. has received personal fees from Servier, Kowa, Medscape, Novo Nordisk, Amgen,
PriMed and Merck; M.P.B. is the Executive Director of CPC, a non-profit academic research
organization affiliated with the University of Colorado, that receives research grant/consulting
funding from: Abbott, Agios, Alexion Pharma, Alnylam, Amgen, Angionetics, ARCA Biopharma,
Array, AstraZeneca, Atentiv, Audentes, Bayer, Better Therapeutics, Brigham and Women’s
Hospital, Bristol-Myers Squibb, Cardiol Therapeutics, CellResearch, Cook Medical,
Cook, CSL Behring, Eidos Therapeutics, EP Trading Co, Esperion Therapeutics, EverlyWell,
Faraday, Fortress Biotech, HDL Therapeutics, Heartflow, Hummingbird Bioscience, Insmed,
Janssen, Kowa Research, Lexicon, Merck, Medtronic, Moderna, Novate Medical, NovoNordisk,
Pfizer, PhaseBio, PPD Development, Prairie Education and Research, Prothena Ciosciences,
Regeneron, Regio Biosciences, Sanifit Therapeutics, Sanofi, Smith and Nephew, Stealth
BioTherapeutics, University of Colorado, Worldwide Clinical Trials, Wraser, Yale Cardiovascular
Research Group. M.P.B. also reports stock in Medtronic and Pfizer and consulting fees
from Audent;
C.P.C. reports research grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI),
Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Novo Nordisk, Pfizer,
Consulting fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics,
Ascendia, BI, BMS, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi.
C.P.C. serve on Data and Safety Monitoring Boards for the Veteran’s Administration,
Applied Therapeutics and NovoNordisk; J.A.d.L reports grant support from Roche Diagnostics
and Abbott Diagnostics, consulting fees from Ortho Clinical Diagnostics, Siemen’s
Health Care Diagnostics, Beckman Coulter, and Quidel; R.P.
G. reports clinical trials/research support from Amgen, Anthos Therapeutics, Daiichi
Sankyo, honoraria for Lectures/CME Programs for Amgen, Centrix, Daiichi Sankyo, Dr.
Reddy’s Laboratories, Medical Education Resources (MER), Medscape, Menarini, Merck,
Pfizer, SAJA Pharmaceuticals, Servier, Shanghai Medical Telescope, Voxmedia, Consultant
fee from Amarin, Amgen, Boston Scientific, CryoLife, CSL Behring, CVS Caremark, Daiichi
Sankyo, Esperion, Gilead, Hengrui, Inari, Janssen, Novartis, Pfizer, PhaseBio Pharmaceuticals,
St. Lukes, Samsung; P.
J. reports research support from Abbott Laboratories, Amgen, Inc., AstraZeneca, LP,
Daiichi-Sankyo, Inc., GlaxoSmithKline, Merck & Co., Inc., Regeneron, Roche Diagnostics
Corporation, and Siemens Healthineers; T.
K. has been a paid consultant for and/or received honoraria payments from AstraZeneca,
Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Edwards, Novartis, Pharmacosmos,
and Vifor and has received research support from Vifor; K.
N. reports research funding through Duke University from Roche Diagnostics; Consulting
honoraria from Beckman-Coulter; M.
O’. reports Grants via Brigham and Women’s Hospital from Amgen, Novartis, AstraZeneca,
Janssen, Intarcia, Merck, Pfizer. Honararia from Novartis, AstraZeneca, Amgen, Janssen;
M.A.
P. reports Research Grant Support from Novartis; consultant to AstraZeneca, Boehringer
Ingelheim and Eli Lilly Alliance, DalCor, GlaxoSmithKline, Lexicon, NHLBI CONNECTs
(Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has
equity in DalCor; N.
R. has no conflic of interest; S.D.
W. reports research grants from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Janssen,
and Merck. He reports consulting fees from AstraZeneca, Boston Clinical Research Institute,
ICON Clinical, Novo Nordisk. Spouse, Dr. Caroline Fox is an employee of Merck. S.D.W.
is a member of the TIMI Study Group, which has received institutional research grant
support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca,
Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline,
Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals,
Roche, Takeda, The Medicines Company, Zora Biosciences;
S.D.W. has been a paid consultant for and has received research support from Boehringer
Ingelheim, and has received honoraria payments from Roche Diagnostics.
T.K. and S.D.W. hold patents (EP 2047275 B1 and US 8951742) and have a licensing contract with Roche
Diagnostics related to GDF-15; E.
B. reports research grants through his institution from Astra Zeneca, Daiichi Sankyo,
Merck and Novartis, and consultancies with Amgen, Boehringer-Ingelheim/Lilly, Bristol
Myers Squibb, Cardurion, Novo Nordisk, and Verve;
M.S. report research grant support through Brigham and Women’s Hospital from Amgen; Anthos
Therapeutics; AstraZeneca; Bayer; Daiichi-Sankyo; Eisai; Intarcia; Ionis; Medicines
Company; MedImmune; Merck; Novartis; Pfizer; Quark Pharmaceuticals. Consulting for:
Althera; Amgen; Anthos Therapeutics; AstraZeneca; Beren Therapeutics; Bristol-Myers
Squibb; DalCor; Dr. Reddy’s Laboratories; Fibrogen; Intarcia; Merck; Moderna; Novo
Nordisk; Silence Therapeutics. Additionally, M.S. is a member of the TIMI Study Group,
which has also received institutional research grant support through Brigham and Women’s
Hospital from Abbott, ARCA Biopharma, Inc., Janssen Research and Development, LLC,
Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, Regeneron, Roche,
and Zora Biosciences.